Beckman Daniella 4

What Happened
Daniella Beckman, a director of Vor Biopharma (VOR), received a grant/award of 53,283 derivative shares reported on June 11, 2026. The filing shows the acquisition price as $0.00 (no cash paid). This was recorded as an award/derivative transaction rather than an open-market purchase or sale.

Key Details

• Transaction date: June 11, 2026; filing date (Form 4): June 12, 2026 (appears timely).
• Amount: 53,283 shares reported as an award (derivative security) at $0.00 per share.
• Shares owned after transaction: not specified in the provided filing summary.
• Vesting: per footnote — one‑thirty‑sixth vests on July 11, 2026 and one‑thirty‑sixth each month thereafter, contingent on continued service.
• Transaction code: A = Award/Grant (derivative). No indication of a sale, cashless exercise, or tax withholding reported in the summary.

Context
Director equity awards are commonly used for compensation and retention. Because these are derivative awards subject to a multi‑month vesting schedule, they are not immediately tradable and do not necessarily signal immediate bullish or bearish sentiment. The filing was submitted the day after the transaction date, which is typical and appears timely.